Independent experts delivering scientific and strategic solutions from discovery through commercialization.

Savanh Chantha-phavong, PhD

Histopathology, Spatial Biology, Digital Pathology and Tissue-based Technologies

Advises partners across academia, biotech, and biopharma on the design validateion, and commercialization of advanced histopathology and spatial biology platforms.

 

Supports development of multiplex IHC and immunofluorescence assays biomarker discovery pipelines, and digital pathology strategies that bridge translational research with applied clinical and commercial programs.

David m. Brown, PHD, PMP

IND project management, mRNA, Synthetic Biology, Virology, Preclinical Strategy, Vaccine Development

With over a decade of hands-on experience in vaccines, mRNA therapeutics, process development, and CMC leadership, David built and led biotech teams, managed multimillion-dollar programs, and guided multiple products from concept through IND submission.

 

As former Vice President at RNAimmune, Inc. and  scientist at the J. Craig Venter Institute, David has led IND filings, CDMO oversight, scientific programs, quality audits, due diligence, and product development.

Kevin Hacker, PHD

AI Strategy, Molecular Biology, and Translational Innovation

Kevin Hacker is an AI strategist and molecular biologist with over 15 years of experience guiding academic and early-stage biotech teams at the intersection of data, discovery, and commercialization. As an industry advisor at UCSF, he works with researchers to translate discoveries into commercial ventures - two teams have already advanced prototypes with IP protection.

He is also Co-Founder of AI Nova Strategy, where he combines MIT-certified training in artificial intelligence with deep molecular biology expertise to help startups integrate AI, multi-omics, and spatial genomics into their research and business strategies.

Kevin’s work bridges scientific innovation, computational strategy, and commercialization - helping organizations move from concept to real-world impact.

Rembert Pieper, PHD

Experienced Scientist Managing Multi-Disciplinary Biological Research Teams, Research Grants and IND Enabling Clinical Biomarker Studies

Served as associate director and professor at J. Craig Venter Institute for 14 years and led grants and contracts with focus on infectious and chronic inflammatory diseases

 

Developed innovative technologies at Biotech companies for clinical biomarker discovery; co-authored 12 patents and multiple patent applications

 

Expertise in proteomics, microbiomics and systems biology including applications to  human subject studies, biomarker discovery and validation (observational, Phase 0, Phase 1) 

Gregory R. Govoni, PHD

Microbiome and Microbial Systems, Molecular Diagnostics, and Translational Biology

Dr. Gregory Govoni is a molecular microbiologist with over 20 years of experience advancing
discovery and translational research across biotechnology and diagnostics. His expertise spans microbiome and host–microbe interactions, microbial and genetic engineering, antimicrobial discovery and development, and molecular diagnostics (infectious and pharmacogenomics). He has extensive experience designing and executing in vivo and in vitro models to evaluate therapeutic efficacy and mechanisms of action. A former NIH R21 Principal Investigator and co-inventor on multiple patents, Dr. Govoni has led cross-functional R&D programs at companies ranging from startups to global leaders such as Thermo Fisher Scientific. He specializes in bridging microbiology, molecular innovation, and strategic development to help organizations translate scientific insight into practical, impactful biotech solutions.